Safety Study of Weekly Semaglutide in Chilean Participants With Type 2 Diabetes

Summary

This study is testing the safety and tolerability of subcutaneous semaglutide in participants with type 2 diabetes (T2D) in Chile. Participants will get a once-weekly subcutaneous injection of semaglutide in doses decided by the study doctor's criteria, according to participant's personal needs. The study will last for about 24 weeks. Participants will have 4 clinic visits and 2 phone calls. Participants will have 3 laboratory tests during the study (blood and urine samples).

Timeline

Start

2022-04-25

Primary completion

2024-01-18

Completion

2024-01-18

Drugs

Indications